Potential of substance P antagonists as antiemetics

Drugs

Volumn 60, Issue 3, 2000, Pages 533-546

  Diemunsch, Pierre ^a   Grelot, Laurent ^b  

^a IRCAD   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 4 (3 OXO 1,2,4 TRIAZOL 5 YLMETHYL) 3 PHENYLMORPHOLINE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; 5 [[3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYL 1 PIPERIDINYL]METHYL] 1,2 DIHYDRO 3H 1,2,4 TRIAZOL 3 ONE; [2 (1H INDOL 3 YLMETHYL) 1 (1 PHENYLETHYLCARBAMOYL)ETHYL]CARBAMIC ACID BENZOFURAN 2 YLMETHYL ESTER; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE; ANTIEMETIC AGENT; APREPITANT; BUSPIRONE; CL 1021; DAPITANT; EZLOPITANT; HSP 117; IPSAPIRONE; NEUROKININ 1 RECEPTOR ANTAGONIST; NOLPITANTIUM; SENDIDE; SEROTONIN 3 ANTAGONIST; SUBSTANCE P ANTAGONIST; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; VOFOPITANT;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; NAUSEA; NEUROTRANSMITTER RELEASE; NONHUMAN; POSTOPERATIVE COMPLICATION; REVIEW; SIDE EFFECT; SWINE; VOMITING;

ANTIEMETICS; CLINICAL TRIALS; HUMANS; INFUSIONS, INTRAVENOUS; RECEPTORS, NEUROKININ-1; SUBSTANCE P; VOMITING;

ANIMALIA; EMESIS; SUS SCROFA;

EID: 0033774032     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060030-00002     Document Type: Review

References (60)

1. An overwiew of emesis
2. Vomiting: Its in and outs
3. 5-HT(1A)receptor agonists as anti-emetic
4. Opioid receptor involvement in emesis and anti-emesis
5. Peptide induced emesis in dogs
6. Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret
7. The mammalian tachykinin receptors
8. Pharmacology of CP-99,994: A non-peptide antagonist of the tachykinin NK-1 receptor
9. The tachykinin NK1 receptor. Part 1: Ligands and mechanisms of cellular activation
10. 1 tachykinin receptor
11. Antinociceptive activity of NK1 receptor antagonists: Nonspecific effects of racemic RP 67,580
12. Characterization of CP-122,721, a nonpeptide antagonist of the neurokinin NK1 receptor
13. 1 receptor, and potent broad-spectrum anti-emetic activity
14. Structural optimization affording 2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenylethoxy)-3(S)-(4fluoro)phenyl-4-(3 -oxo-1,2,4-triazol-5-yl) methyl-morpholine a potent orally active, long-acting morpholine acetal human NK-1 receptor antagonist
15. 1 receptor anatagonist, CP-99,994, in ferrets
16. Ethanol-induced emesis in the house musk shrew, Suncus murinus
17. The effect of CP-99994 on the responses of provocative motion in the cat
18. 1 receptor antagonist, CP-99,994 in antagonizing the acute and delayed emesis induced by cisplatin in ferret
19. 1 receptor antagonists
20. The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in ferret
21. 1 receptor antagonist CP-99,994
22. 1) receptor antagonist CP-99,994
23. The tachykinins and emesis: Towards complete control?
24. 1 receptor
25. 1 receptor antagonist, in ferrets
26. The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor, GR203040
27. 1 receptor antagonists: The identification of an exceptionally potent orally active antiemetic compound
28. 1 receptor antagonist
29. A neurokinin 1 receptor antagonist reduced hypersalivation and gastric contractility related to emesis in dogs
30. The tachykinin NK1 receptor antagonist GR 205171 prevents vagal stimulation-induced retching but not neuronal transmission from emetic vagal afferents to solitary nucleus neurons in dogs
31. 1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets
32. 1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret
33. Anti-emetic effects of a novel NK-1 receptor antagonist HSP-117 in ferrets
34. 1 receptor antagonist, in the ferret
35. 1 receptor antagonists is mediated centrally in the ferret
36. 1 receptor antagonist L-733,060 in gerbils
37. The piglet as a suitable animal model for studying the delayed phase of chemotherapy-induced delayed emesis
38. Repeated administration of the 5-HT3 receptor antagonist Granisetron reduces the incidence of delayed cisplatin-induced emesis in the piglet
39. 1 or 5-HT3 receptor antagonist in the house musk shrew, Suncus murinus
40. GR205171 blocks apomorphine and amphetamine-induced conditioned taste aversions
41. Role of substance P in emesis
42. Capsaicin in 4th ventricle abolishes retching and transmission of emetic vagal afferents to solitary nucleus neurons
43. The effects of centrally injected NK1 receptor antagonists on emesis in the ferret
44. Organisation of the vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem
45. Neuroactive substances in the dorsal vagal complex of the medulla oblongata: Nucleus of the tractus solitarius, area postrema and dorsal motor nucleus of the vagus
46. Neurochemistry of visceral afferent neurones
47. The afferent peptidergic innervation of the upper gastrointestinal tract
48. 1-antagonists, GR203040 and GR205171
49. Neurokinin receptor antagonists; therapeutic potential in the treatment of pain syndromes
50. Randomized phase II study of the neurokinin 1 receptor antagonist CJ- 11,974 in the control of cisplatin-induced emesis
51. 1-receptor antagonist
52. 1 receptor antagonist GR205171 in combination with ondansetron
53. 1 receptor antagonist GR205171 in the treatment of established PONV following major gynaecological surgery
54. 1 receptor antagonist to prevent delayed emesis after cisplatin
55. Comparison of a new NK1 antagonist (CP122,721) to ondansetron in the prevention of postoperative nausea and vomiting
56. 1 antagonist, L-758,298, to ondansetron in the prevention of cisplatin-induced emesis
57. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain
58. Current therapy for management of postoperative nausea and vomiting: The 5-HT3 receptor antagonists